Cover Image
市場調查報告書

Critical Pharmaceuticals Limited:產品平台分析

Critical Pharmaceuticals Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256000
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
Critical Pharmaceuticals Limited:產品平台分析 Critical Pharmaceuticals Limited - Product Pipeline Review - 2015
出版日期: 2015年05月13日 內容資訊: 英文 27 Pages
簡介

Critical Pharmaceuticals Limited 是開發活用了獨自的藥物輸送技術的生技藥品產品系列的臨床階段的生物科技企業。譬如,製造著生長激素的鼻腔給藥製劑,也致力於非侵入性的生技藥品通知技術,及難度高(貴)的小分子藥物的開發。

本報告提供Critical Pharmaceuticals Limited 提供著的治療藥開發平台的現狀及各開發階段比較分析,藥物標的,作用機制,給藥途徑,各分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Critical Pharmaceuticals Limited的基本資料

  • Critical Pharmaceuticals Limited概要
  • 主要資訊
  • 企業資料

Critical Pharmaceuticals Limited:R&D概要

  • 主要的治療範圍

Critical Pharmaceuticals Limited:開發平台(管線)的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Critical Pharmaceuticals Limited:開發中產品概況

  • 臨床實驗階段有的開發中產品
    • 第一階段有的產品/聯合治療模式
  • 初期階段有的開發中產品
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Critical Pharmaceuticals Limited:藥物簡介

  • CP-024
  • teriparatide
  • bevacizumab SR
  • CP-053
  • somatropin
  • risperidone

Critical Pharmaceuticals Limited:開發平台分析

  • 按標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Critical Pharmaceuticals Limited:最近的開發平台趨勢

Critical Pharmaceuticals Limited:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07071CDB

Summary

Global Markets Direct's, 'Critical Pharmaceuticals Limited - Product Pipeline Review - 2015', provides an overview of the Critical Pharmaceuticals Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Critical Pharmaceuticals Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Critical Pharmaceuticals Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Critical Pharmaceuticals Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Critical Pharmaceuticals Limited's pipeline products

Reasons to buy

  • Evaluate Critical Pharmaceuticals Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Critical Pharmaceuticals Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Critical Pharmaceuticals Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Critical Pharmaceuticals Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Critical Pharmaceuticals Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Critical Pharmaceuticals Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Critical Pharmaceuticals Limited Snapshot
    • Critical Pharmaceuticals Limited Overview
    • Key Information
    • Key Facts
  • Critical Pharmaceuticals Limited - Research and Development Overview
  • Key Therapeutic Areas
  • Critical Pharmaceuticals Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Critical Pharmaceuticals Limited - Pipeline Products Glance
    • Critical Pharmaceuticals Limited - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Critical Pharmaceuticals Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Critical Pharmaceuticals Limited - Drug Profiles
    • CP-024
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • teriparatide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CP-053
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • risperidone
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Critical Pharmaceuticals Limited - Pipeline Analysis
    • Critical Pharmaceuticals Limited - Pipeline Products by Target
    • Critical Pharmaceuticals Limited - Pipeline Products by Route of Administration
    • Critical Pharmaceuticals Limited - Pipeline Products by Molecule Type
    • Critical Pharmaceuticals Limited - Pipeline Products by Mechanism of Action
  • Critical Pharmaceuticals Limited - Recent Pipeline Updates
  • Critical Pharmaceuticals Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Critical Pharmaceuticals Limited, Key Information
  • Critical Pharmaceuticals Limited, Key Facts
  • Critical Pharmaceuticals Limited - Pipeline by Indication, 2015
  • Critical Pharmaceuticals Limited - Pipeline by Stage of Development, 2015
  • Critical Pharmaceuticals Limited - Monotherapy Products in Pipeline, 2015
  • Critical Pharmaceuticals Limited - Phase I, 2015
  • Critical Pharmaceuticals Limited - Preclinical, 2015
  • Critical Pharmaceuticals Limited - Discovery, 2015
  • Critical Pharmaceuticals Limited - Pipeline by Target, 2015
  • Critical Pharmaceuticals Limited - Pipeline by Route of Administration, 2015
  • Critical Pharmaceuticals Limited - Pipeline by Molecule Type, 2015
  • Critical Pharmaceuticals Limited - Pipeline Products by Mechanism of Action, 2015
  • Critical Pharmaceuticals Limited - Recent Pipeline Updates, 2015

List of Figures

  • Critical Pharmaceuticals Limited - Pipeline by Top 10 Indication, 2015
  • Critical Pharmaceuticals Limited - Pipeline by Stage of Development, 2015
  • Critical Pharmaceuticals Limited - Monotherapy Products in Pipeline, 2015
  • Critical Pharmaceuticals Limited - Pipeline by Top 10 Target, 2015
  • Critical Pharmaceuticals Limited - Pipeline by Top 10 Route of Administration, 2015
  • Critical Pharmaceuticals Limited - Pipeline by Top 10 Molecule Type, 2015
  • Critical Pharmaceuticals Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top